Jacobio Pharmaceuticals Group Co., Ltd. has entered into agreements involving a capital increase and equity transfer related to its subsidiary, Jacoray Pharmaceutical Technology Co., Ltd. Following the transaction, Beijing Jacobio, an industry partner, and Oceanpine Capital will hold 80%, 10%, and 10% equity interests in Jacoray, respectively. As a result, Jacoray will no longer be a wholly-owned subsidiary of Beijing Jacobio. Proceeds from the transaction, after tax and expenses, are intended to support research and development, production, and commercialization of the company's Pan-KRAS inhibitor and other innovative oncology therapies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief on October 15, 2025, and is solely responsible for the information contained therein.